Zobrazeno 1 - 10
of 231
pro vyhledávání: '"Viza D"'
Publikováno v:
Transplantation; March 2023, Vol. 9 Issue: 3 p228-239, 12p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Advances in Tumor Virology. 2:7-20
Transfer factor (TF) is a lymphocyte extract of low molecular weight capable of transferring antigen-specific information to T-lymphocytes. A number of reports have documented its efficacy in the control of acute viral infections, particularly those
Publikováno v:
Medical Hypotheses. 67:601-608
Avian influenza A subtype H5N1 virus with its recombination potential with the human influenza viruses presents a threat of producing a pandemic. The consensus is that the occurrence of such a pandemic is only a matter of time. This is of great conce
Autor:
D. Menniti, Maver P, P. Romagnoli, Viza D, Riolo U, C De Vinci, A. Palareti, E. Aiello, G. Pizza, Cuzzocrea D, P Zucchelli, V. Fornarola, G. Corrado, Dragoni E, G LoConte
Publikováno v:
Biotherapy. 9:123-132
As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). Th
Publikováno v:
Biotherapy. 9:67-72
Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer factor (TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment was a
Publikováno v:
Biotherapy. 9:61-66
Recurrent ocular herpes is an insoluble problem for the clinician. As cellular immunity plays an important role in controlling herpes relapses, and other studies have shown the efficacy of HSV-specific transfer factor (TF) for the treatment of herpes
Publikováno v:
Biotherapy. 9:81-86
Specific Human Herpes virus-6 (HHV-6) transfer factor (TF) preparation, administered to two chronic fatigue syndrome patients, inhibited the HHV-6 infection. Prior to treatment, both patients exhibited an activated HHV-6 infection. TF treatment signi
Autor:
G. Pizza, Caterina De Vinci, Francesco Gritti, E. Raise, Vincenzo Colangeli, H. Hugh Fudenberg, Viza D, Francesco Chiodo
Publikováno v:
Biotherapy. 9:41-47
Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF